Valuation : UCB SA

Market Cap 39.01B 45.39B 36.75B 33.5B 62.64B 4,318B 62.89B 435B 168B 2,205B 170B 167B 6,962B P/E 2026 *
20.4x
P/E 2027 * 16.9x
Enterprise Value 39.32B 45.75B 37.04B 33.76B 63.13B 4,352B 63.38B 439B 169B 2,222B 172B 168B 7,016B EV / Sales 2026 *
4.52x
EV / Sales 2027 * 3.84x
Free-Float
61.59%
Yield 2026 *
0.71%
Yield 2027 * 0.73%
1 day-1.15%
1 week-5.98%
Current month-5.03%
1 month-8.13%
3 months-20.97%
6 months-18.60%
Current year-15.09%
1 week 118.62
Extreme 118.62
128.75
1 month 118.62
Extreme 118.62
131.13
Current year 118.62
Extreme 118.62
168.76
1 year 114.52
Extreme 114.525
168.76
3 years 34.85
Extreme 34.85
168.76
5 years 32.82
Extreme 32.82
168.76
10 years 29.2
Extreme 29.2
168.76
Manager TitleAgeSince
Chief Executive Officer 67 01/01/2015
Director of Finance/CFO 60 01/07/2020
Chief Tech/Sci/R&D Officer 59 01/05/2024
Director TitleAgeSince
Director/Board Member 55 01/01/2012
Director/Board Member 67 01/01/2015
Director/Board Member 56 24/04/2014
Change 5-day change 1-year change 3-year change Capi.($)
-1.15%-5.98% - - 45.88B
-0.33%-1.96%+44.63%-2.77% 80.91B
-2.05%-0.64%-19.76%-36.79% 60.46B
-3.36%-12.10%+446.15%+25.98% 56.02B
+0.83%-4.47%-8.40%+30.44% 49.63B
-1.11%-6.36%-2.76%+147.94% 45.88B
-0.83%-2.46%+49.08%-18.63% 31.4B
+1.29%+0.80%+45.58%+96.95% 25.22B
-2.00%-3.35%-2.29%+177.79% 22.25B
-3.02%-3.10%+60.58%+104.24% 16.59B
Average -0.84%-1.29%+68.09%+58.35% 43.15B
Weighted average by Cap. -0.69%-1.13%+78.57%+38.24%

Financials

2026 *2027 *
Net sales 8.69B 10.12B 8.19B 7.47B 13.96B 962B 14.02B 97B 37.48B 491B 37.98B 37.15B 1,552B 9.68B 11.26B 9.12B 8.31B 15.54B 1,071B 15.6B 108B 41.72B 547B 42.27B 41.35B 1,727B
Net income 1.93B 2.25B 1.82B 1.66B 3.1B 214B 3.11B 21.55B 8.33B 109B 8.44B 8.25B 345B 2.32B 2.71B 2.19B 2B 3.73B 257B 3.75B 25.93B 10.02B 131B 10.15B 9.93B 415B
Net Debt 306M 356M 288M 262M 491M 33.82B 493M 3.41B 1.32B 17.27B 1.33B 1.31B 54.52B -1.81B -2.1B -1.7B -1.55B -2.9B -200B -2.91B -20.17B -7.79B -102B -7.9B -7.72B -323B
Logo UCB SA
UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.
Employees
9,000
Date Price Change Volume
09/09/26 $118.67 -1.15% 39,757
08/09/26 $120.06 -1.90% 46,077
04/09/26 $122.38 -4.82% 23,697
03/09/26 $128.58 +0.69% 41,362
02/09/26 $127.69 +1.16% 25,816
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
204.60EUR
Average target price
285.00EUR
Spread / Average Target
+39.30%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!